Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24272197 | 0.83 | ALDH1A1 (0.39) | ALDH1A1LMNAHTTGAAHPGD | |
| SCHEMBL12120606 | 0.80 | — | — | |
| SCHEMBL13981499 | 0.80 | LOX (0.36) | — | |
| SCHEMBL20259464 | 0.78 | DAO (0.35) | DAOALDH1A1LMNAHTTGAA | |
| SCHEMBL21793210 | 0.77 | DPP4 (0.32) | — | |
| SCHEMBL17428955 | 0.77 | LMNA (0.45) | DAOALDH1A1LMNAHTTGAA | |
| SCHEMBL2823187 | 0.75 | PTPN1 (0.34) | — | |
| SCHEMBL22845183 | 0.74 | DAO (0.38) | DAOALDH1A1LMNAHPGDTP53 | |
| SCHEMBL10861961 | 0.74 | TP53 (0.39) | DAOALDH1A1GAATP53RAB9A | |
| SCHEMBL1700982 | 0.72 | DAO (0.41) | DAOALDH1A1LMNAHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567331-A | Synthesis method of 1, 2-dithioethane compound and 1, 4-dithiane | 河北北方学院 | 2024-02-20 | — | — | CN | disclosed |
| US-20230381159-A1 | SMALL MOLECULE INHIBITORS OF CORONAVIRUS ATTACHMENT AND ENTRY, METHODS AND USES THEREOF | UNIVERSITY OF MIAMI | 2023-11-30 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220315706-A1 | PHOTOPOLYMERIZABLE THERMOPLASTICS AND METHODS OF MAKING AND USING SAME | UNIV COLORADO REGENTS (US) | 2022-10-06 | — | — | US | disclosed |
| US-11377422-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220117969-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADENOMYOSIS AND RECTOVAGINAL ENDOMETRIOSIS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2022-04-21 | — | — | US | disclosed |
| US-20210128578-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210061763-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2021-03-04 | — | — | US | disclosed |
| WO-2021023876-A1 | GNRH ANTAGONISTS FOR THE TREATMENT OF ESTROGEN-DEPENDENT DISORDERS | ObsEva S.A. (CH) | 2021-02-11 | — | — | WO | disclosed |
| US-10781200-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-9999625-B2 | Pyrrolobenzodiazepine compounds | FEMTOGENIX LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2017-09-14 | — | — | US | disclosed |
| US-9714241-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-25 | — | — | US | disclosed |
| US-20170050971-A1 | PYRROLOBENZODIAZEPINE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | US | disclosed |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-7285565-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | DAO 4627/4885ALDH1A1 3381/4885LMNA 2298/4885 |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | DAO 641/4885ALDH1A1 354/4885LMNA 4025/4885 |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | DAO 641/4885ALDH1A1 354/4885LMNA 4025/4885 |
| US-20220117969-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADENOMYOSIS AND RECTOVAGINAL ENDOMETRIOSIS | GNRHR, PGR, NR5A1 | DAO 181/4885ALDH1A1 1188/4885LMNA 1190/4885 |
| US-20230381159-A1 | SMALL MOLECULE INHIBITORS OF CORONAVIRUS ATTACHMENT AND ENTRY, METHODS AND USES THEREOF | ACE2, ACE, SARS1 | DAO 1880/4885ALDH1A1 2115/4885LMNA 2523/4885 |
| US-11377422-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | DAO 2669/4885ALDH1A1 2736/4885LMNA 2685/4885 |
| US-20170050971-A1 | PYRROLOBENZODIAZEPINE COMPOUNDS | DRD1, DRD2, DRD3 | DAO 554/4885ALDH1A1 750/4885LMNA 705/4885 |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | SLC5A2, IAPP, GPR119 | DAO 746/4885ALDH1A1 1333/4885LMNA 1800/4885 |
| US-10781200-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | DAO 2963/4885ALDH1A1 1717/4885LMNA 2032/4885 |
| US-20210061763-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | DAO 2669/4885ALDH1A1 2736/4885LMNA 2685/4885 |
| US-20210128578-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | DAO 2669/4885ALDH1A1 2736/4885LMNA 2685/4885 |
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | DAO 4627/4885ALDH1A1 3381/4885LMNA 2298/4885 |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | DAO 2410/4885ALDH1A1 1138/4885LMNA 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.